We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

FUJIREBIO

Fujirebio is a global leader in the field of IVD testing with more than 50 years’ experience in the conception, devel... read more Featured Products: More products

Download Mobile App





Fujirebio Showcases Range of Novel Testing Solutions

By LabMedica International staff writers
Posted on 14 Nov 2023
Print article
Image: The LUMIPULSE G series of instruments was on display at MEDICA 2023 (Photo courtesy of Fujirebio)
Image: The LUMIPULSE G series of instruments was on display at MEDICA 2023 (Photo courtesy of Fujirebio)

Fujirebio (Tokyo, Japan) is showcasing its LUMIPULSE G series of chemiluminescent enzyme immunoassay (CLEIA) analyzers and kits for fully automated testing at MEDICA 2023. The LUMIPULSE G series includes the LUMIPULSE G1200 fully automated immunoassay instrument which uses a unique mono test cartridge concept. It has a true throughput of 120 tests per hour and provides outstanding flexibility and easy handling in hospitals and clinical laboratories.

Fujirebio is also highlighting the latest member of the LUMIPULSE G series, the LUMIPULSE G600II which is a compact and robust benchtop analyzer with a constant throughput of 60 tests per hour. The system uses a unique mono test cartridge concept (the same cartridge concept as the mid-sized LUMIPULSE G1200 analyzer) and offers outstanding flexibility and easy handling to hospitals and clinical laboratories. The easy-to-use analyzer provides a perfect fit in laboratories aiming for personalized workflow solutions without compromising testing quality. Fujirebio offers a number of kits for fully automated testing on the LUMIPULSE G series of CLEIA analyzers.

This includes Lumipulse G 25-OH Vitamin D is an immunoreaction cartridge for in vitro diagnostic (IVD) use for the quantitative determination of 25-hydroxyvitamin D (25-OH-D) in human serum or plasma to be used in the assessment of Vitamin D sufficiency. Fujirebio is highlighting the Lumipulse G Aldosterone immunoreaction cartridges for the quantitative measurement of aldosterone in human serum, plasma, or urine. Also being showcased at MEDICA 2023 is the Lumipulse G B•R•A•H•M•S PCT immunoreaction cartridges for IVD use with a two-step sandwich immunoassay method on the LUMIPULSE G system for the quantitative determination of procalcitonin (PCT) in human serum and plasma.

Related Links:
Fujirebio 

New
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
New
Cryptosporidium Infection Test
Crypto (Card) Rapid Test

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.